CompanyGraph
Shanghai MicroPort Endovascular MedTech Co., Ltd.
688016 · SSE · China
endovastec.comFinancials as of FY2025
What stands out
- Revenue is growing, but receivables have grown faster over the last six to eight years
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleMarket cap is $1.69B, above the global median of $1.15B
- PositionOperating margin is 48.8%, higher than 95% of its Medical Devices peers (median 7.3%)
- Interpretations14 currently firing — 14
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
1.08%Below 5Y avg (1.58%)
Annual Rate
CNY 1.00Paid annual
Payout Ratio
33.8%Sustainable
Payback Period
92.5 yr
Last Ex-Dividend
Jun 5, 2026
The reported statements, read against the company's own industry.
What stands out
- Revenue is growing, but receivables have grown faster over the last six to eight years
Financials view
Market Capitalization
11.39BCNY1.69B · vs all stocks (USD)
Trailing P/E
18.60xvs Medical Devices peers
Revenue (TTM)
1.39BCNY206.51M · vs all stocks (USD)
Profit Margin
42.38%vs Medical Devices peers
Beta
0.0540xvs all stocks
52-Week Change
-23.65%vs all stocks
Market Capitalization
11.39BCNY1.69B · vs all stocks (USD)
Enterprise Value
9.09BCNY1.35B · vs all stocks (USD)
Trailing P/E
18.60xvs Medical Devices peers
Forward P/E
15.28xvs Medical Devices peers
Price to Sales (TTM)
8.06xvs Medical Devices peers
Price to Book (MRQ)
2.60xvs Medical Devices peers
Enterprise to Revenue
6.54xvs Medical Devices peers
Enterprise to EBITDA
13.19xvs Medical Devices peers
Gross Margin
73.13%vs Medical Devices peers
Profit Margin
42.38%vs Medical Devices peers
Operating Margin
48.83%vs Medical Devices peers
Return on Assets (TTM)
8.36%vs Medical Devices peers
Return on Equity (TTM)
14.26%vs Medical Devices peers
Revenue (TTM)
1.39BCNY206.51M · vs all stocks (USD)
Revenue per Share (TTM)
11.52CNYUpdated Aug 21, 2026Quarterly Revenue Growth
11.50%vs Medical Devices peers
Gross Profit (TTM)
990.30MCNY147.27M · vs all stocks (USD)
EBITDA (TTM)
716.77MCNY106.59M · vs all stocks (USD)
Net Income (TTM)
588.53MCNY87.52M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
19.40%vs Medical Devices peers
Operating Cash Flow (TTM)
543.72MCNY80.86M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
239.51MCNY35.62M · vs all stocks (USD)
Trailing Annual Dividend Rate
1.00CNYUpdated Aug 21, 2026Trailing Annual Dividend Yield
1.08%vs all stocks
5-Year Average Dividend Yield
1.58%vs all stocks
Payout Ratio
33.81%vs Medical Devices peers
Minority Interest (Equity)
23.18MCNYFY2025 · Dec 31, 2025Revenue
1.35BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
390.57MCNYFY2025 · Dec 31, 2025Gross Profit
960.06MCNYFY2025 · Dec 31, 2025Operating Income
651.10MCNY96.82M · vs all stocks (USD)
Pre-tax Income
653.49MCNYFY2025 · Dec 31, 2025Income Tax Expense
98.83MCNYFY2025 · Dec 31, 2025Net Income
554.66MCNYFY2025 · Dec 31, 2025EBIT
655.65MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
751.92MCNYFY2025 · Dec 31, 2025Research & Development
67.79MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
139.02MCNYFY2025 · Dec 31, 2025Other Operating Expenses
12.04MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
10.93MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
2.16MCNYFY2025 · Dec 31, 2025EPS (Basic)
4.65CNYFY2025 · Dec 31, 2025EPS (Diluted)
4.65CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
121.15MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
121.15MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
554.66MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
8.67MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
637.40MCNYFY2025 · Dec 31, 2025Free Cash Flow
334.37MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
1.89BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
554.66MCNYFY2025 · Dec 31, 2025Other Non-cash Items
17.53MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
90.93MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-25.72MCNYFY2025 · Dec 31, 2025Capital Expenditures
-303.03MCNYFY2025 · Dec 31, 2025Purchase of Investments
-5.03BCNYFY2025 · Dec 31, 2025Sale of Investments
4.95BCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-387.06MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
126.00MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-140.00MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-201.83MCNYFY2025 · Dec 31, 2025Other Financing Charges
-134.08MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-349.92MCNYFY2025 · Dec 31, 2025Shares Outstanding
123.26MSharesUpdated Aug 21, 2026Float Shares
71.15MSharesUpdated Aug 21, 2026% Held by Insiders
42.60%vs all stocks
% Held by Institutions
7.20%vs all stocks
Total Cash (MRQ)
2.08BCNY309.46M · vs all stocks (USD)
Total Cash per Share (MRQ)
17.22CNYUpdated Aug 21, 2026Total Debt (MRQ)
12.06MCNY1.79M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0028xvs Medical Devices peers
Current Ratio (MRQ)
6.94xvs Medical Devices peers
Book Value per Share (MRQ)
34.91CNYUpdated Aug 21, 2026Total Assets
4.64BCNY690.19M · vs all stocks (USD)
Total Current Assets
2.80BCNYFY2025 · Dec 31, 2025Total Liabilities
542.63MCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.84BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
133.38MCNYFY2025 · Dec 31, 2025Total Current Liabilities
409.25MCNYFY2025 · Dec 31, 2025Cash
2.00BCNYFY2025 · Dec 31, 2025Cash Equivalents
6.44MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
2.00BCNYFY2025 · Dec 31, 2025Other Short-term Investments
100.37MCNYFY2025 · Dec 31, 2025Accounts Receivable
368.08MCNYFY2025 · Dec 31, 2025Inventory
272.30MCNYFY2025 · Dec 31, 2025Accounts Payable
60.13MCNYFY2025 · Dec 31, 2025Short-term Debt
10.61MCNYFY2025 · Dec 31, 2025Other Current Liabilities
14.38MCNYFY2025 · Dec 31, 2025Long-term Debt
4.37MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
11.07MCNYFY2025 · Dec 31, 2025Common Stock (Book)
123.26MCNYFY2025 · Dec 31, 2025Retained Earnings
1.45BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
4.10BCNY609.49M · vs all stocks (USD)
Treasury Stock
240.11MCNYFY2025 · Dec 31, 202552-Week Low
83.33CNYUpdated Aug 21, 202652-Week High
121.99CNYUpdated Aug 21, 202652-Week Change
-23.65%vs all stocks
Beta
0.0540xvs all stocks
50-Day MA
91.57CNYUpdated Aug 21, 2026200-Day MA
97.20CNYUpdated Aug 21, 2026Avg 10-Day Volume
1.67MSharesUpdated Aug 21, 2026Avg 30-Day Volume
1.67MSharesUpdated Aug 21, 2026Diluted EPS (TTM)
4.88CNYUpdated Aug 21, 202614 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Cash Elevated Relative to Current Liabilities and Total Assets
Its cash covers more of its near-term bills than in its industry, and is a large share of everything it owns.
Reads
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
Liquidity Ratios Elevated
It can cover near-term bills from cash alone, not just from inventory.
Reads
Low-Leverage Liquidity Configuration
Cash on hand covers most or all of its debt, and its equity share of assets is high for its industry.
Reads
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
How does this company use capital?
Cash Backing With Revenue And Income Streaks
Revenue has risen in each of three years, profit in all three, and it holds more cash than debt.
Reads
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion Levels
Its gross margin and its cash margin are high for its industry, and its operating margin is high outright.
Reads
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Operating Income Growing With Multi-Year Revenue Growth
Revenue up in each of five years, with operating income up in each of four.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Net Levels
Its gross and net margins are high for its industry, and its operating margin is high outright.
Reads
Revenue Growing With Receivables Growing
Revenue has risen three years, and what customers owe has risen with it.
Reads
ROE, ROA, And Operating ROA Elevated
It earns more on its equity than its industry does, and on its assets too — not on borrowing alone.
Reads
Is this company growing?
Revenue Growth With Elevated Margin
Revenue up in each of five years, while its operating margin stays high.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is 48.8%, higher than 95% of its Medical Devices peers (median 7.3%)Significant
Operating margin: 0.49Industry median: 0.07Industry P95: 0.37Peers compared: 59.00
Profit margin is 42.4%, higher than 95% of its Medical Devices peers (median 3.6%)Significant
Profit margin: 0.42Industry median: 0.04Industry P95: 0.31Peers compared: 59.00
Structural Tensions
Revenue is growing, but receivables have grown faster over the last six to eight yearsSignificant
Revenue Growth YoY: 0.12Receivables vs revenue divergence: 4.67
Financial Health
Altman Z-Score 14.4: safe zoneNotable
Altman Z-Score: 14.40
High earnings qualityNotable
Earnings Quality Score: 0.52
High structural barrier to entryNotable
Barrier to Entry: 0.62
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Market cap is $1.69B, above the global median of $1.15BNotable
Market cap (USD): 1,693,353,984.065Global Median: 1,146,734,693.424
Levered free cash flow is $35.62M, above the global median of $16.24MNotable
Levered free cash flow (USD): 35,617,444.064Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Cofoe Medical Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Alembic Pharmaceuticals Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jubilant Pharmova Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Conba Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Taysha Gene Therapies Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
4DMedical Limited
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
MapLight Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Pharmablock Sciences Nanjing Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Henan Lingrui Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Inventisbio Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Companies that share active interpretations — structural patterns currently present in both stocks.
United States Lime & Minerals Inc.
13 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesCash Backing With Revenue And Income StreaksROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedRevenue Growing With Receivables GrowingCash Elevated Relative to Current Liabilities and Total AssetsLiquidity Ratios ElevatedRevenue Growth With Elevated MarginIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsLow-Leverage Liquidity ConfigurationMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Shanghai Bochuan Electronic Co., Ltd.
12 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesCash Backing With Revenue And Income StreaksROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedRevenue Growing With Receivables GrowingOperating Income Growing With Multi-Year Revenue GrowthLiquidity Ratios ElevatedRevenue Growth With Elevated MarginIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsLow-Leverage Liquidity Configuration
Wiselink Co., Ltd.
12 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesCash Backing With Revenue And Income StreaksROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedOperating Income Growing With Multi-Year Revenue GrowthCash Elevated Relative to Current Liabilities and Total AssetsLiquidity Ratios ElevatedRevenue Growth With Elevated MarginIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsLow-Leverage Liquidity Configuration